Recent Progress of Src SH2 and SH3 Inhibitors as Anticancer Agents

Title: Recent Progress of Src SH2 and SH3 Inhibitors as Anticancer Agents

Volume: 17 Issue: 12

Author(s): X.-L. Lu, X. Cao, X.-Y. Liu and B.-H. Jiao

Affiliation:

Keywords: Protein tyrosine kinases, Src kinases, SH2, SH3, inhibitor, peptidomimetic, nonpeptide, progress

Abstract: Src family tyrosine kinases (SFKs) play key roles in regulating signal transduction in cellular processes. However, hyper-activated SFKs lead to uncontrolled cell proliferation and cancers. For both Src SH2 and SH3 domains involve in the regulation of tumorigenesis signal pathways, the SH2 and SH3 inhibition strategies are expected to block the protein-protein interactions between SFKs and their corporation proteins to abolish the signal transduction. Many inhibitors of SH2 and SH3 domain have been identified. Herein, some predominant examples of these inhibitors are reviewed.

Cite this article as:

Lu X.-L., Cao X., Liu X.-Y. and Jiao B.-H., Recent Progress of Src SH2 and SH3 Inhibitors as Anticancer Agents, Current Medicinal Chemistry 2010; 17 (12) . https://dx.doi.org/10.2174/092986710790827861